| Mortality (100 patients-year) in studies | All-cause | Infection | Cardiovascular | Malignancies | Lupus nephritis | Lupus | Unknown | Suicide |
|---|
|
|---|
| All | 1.73 (1.37–2.11) | 0.62 (0.46–0.79) | 0.41 (0.31–0.51) | 0.17 (0.12–0.24) | 0.20 (0.14–0.27) | 0.15 (0.09–0.21) | 0.33 (0.24- 0.42) | 0.16 (0.11–0.23) |
| Rituximab | 1.14 (0.42–0.22) | 0.37 (0.03–1.06) | 0.37 (0.03–1.06) | 0.25 (0.007–0.84) | 0.25 (0.007–0.84) | 0.25 (0.007–0.84) | 0.50 (0.08–1.27) | 0.25 (0.007–0.84) |
| Cyclophosphamide | 3.79 (2.74–5.02) | 1.45 (0.89–2.13) | 0.97 (0.63–1.38) | 0.35 (0.16–0.61) | 0.40 (0.20–0.67) | 0.32 (0.14–0.56) | 0.51 (0.25–0.85) | 0.27 (0.11–0.51) |
| Mycophenolate | 2.35 (1.05–4.14) | 1.55 (0.66–2.82) | 0.45 (0.09–1.08) | 0.52 (0.12–1.19) | 0.45 (0.09–1.08) | 0.59 (0.16–1.30) | 0.67 (0.20–1.40) | 0.45 (0.09–1.08) |
| Azathioprine | 1.51 (0.54–2.98) | 0.66 (0.28–1.20) | 0.73 (0.33–1.30) | 0.28 (0.06–0.67) | 0.35 (0.09–0.77) | 0.17 (0.01–0.49) | 0.17 (0.01–0.49) | 0.33 (0.08–0.74) |
| Cyclosporine | 0.64 (0.27–1.19) | 0.17 (0.02–0.48) | 0.14 (0.01.-0.42) | 0.17 (0.02–0.48) | 0.14 (0.01–0.42) | 0.14 (0.01–0.42) | 0.51 (0.19–0.97) | 0.14 (0.01–0.42) |
| Leflunomide | 7.82 (0.79–21.11) | 2.64 (0.08–12.24) | 7.82 (0.79–21.11) | 2.64 (0.08–12.24) | 2.64 (0.08–12.24) | 2.64 (0.08–12.24) | 2.64 (0.08–12.24) | 2.64 (0.08–12.24) |
| Abatacept | 2.27 (0.89–4.30) | 0.79 (0.12–2.07) | 0.53 (0.03–1.56) | 0.23 (0.0001–0.89) | 0.23 (0.0001–0.89) | 0.23 (0.0001–0.89) | 0.63 (0.11–1.60) | 0.23 (0.0001–0.89) |
| Belimumab | 0.74 (0.39–1.22) | 0.18 (0.006–0.62) | 0.05 (0.0004–0.21) | 0.11 (0.0090–0.33) | 0.05 (0.0004–0.21) | 0.11 (0.0090–0.33) | 0.11 (0.0090–0.33) | 0.08 (0.003–0.29) |
| Tacrolimus | 3.34 (0.07–11.12) | 3.34 (0.07–11.12) | 1.65 (0.02–7.34) | 0.26 (0.16–0.39) | 1.65 (0.02–7.34) | 1.65 (0.02–7.34) | 1.65 (0.02–7.34) | 1.65 (0.02–7.76) |